NanoEntek announced on the 15th that it will integrate AAI Healthcare as a subsidiary, aiming to advance its global comprehensive life care business.
NanoEntek's goal is to establish a competitive advantage in the future digital healthcare market, including telemedicine, through vertical integration. The company noted that it will strengthen market competitiveness by combining the capabilities of both companies to build a seamless value chain from medical device manufacturing to patient health management.
NanoEntek possesses technological capabilities in in vitro diagnostics (IVD) and life sciences (LS). Products such as the "FREND system" and the cell analysis technology-based "CGT platform" have received approval from the U.S. Food and Drug Administration (FDA). Recently, it has been expanding its business into K-beauty through collaboration with L'Oreal in the skincare sector.
AAI Healthcare has access to a domestic hospital network, insurance companies, and a databases of business-to-business (B2B) customers, as well as a digital healthcare platform. The healthcare platform offers premium health consultation services primarily staffed by professional nurses, providing real-time responses 24 hours a day, 365 days a year. AAI Healthcare recorded revenue of 6 billion won, operating profit of 900 million won, and net profit of 1.4 billion won last year. Its debt ratio is about 10%, indicating a stable financial status.
NanoEntek plans to expand the domestic supply of the FREND system based on the hospital network secured by AAI Healthcare and diversify channels for sample collection for research and development.
A company official said, "We will systematically promote collaboration to maximize synergies after successfully completing a comprehensive stock exchange with AAI Healthcare."